Acupressure as Long-term Intervention to Slow the Progression of Early/Mild Alzheimer's Disease

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age60-85
SponsorThe University of Hong Kong

About this trial

This is an assessor-blinded, randomized controlled trial. A total of 188 older adults aged 60-85 years with early/mild AD will be recruited from care and attention homes for the elderly and elderly activity centers. Participants will be randomly assigned to receive least acupressure control (LAC, n = 94) and Comfy Acupressure for the Elderly (CAE, n = 94), administered by caregivers (i.e., trained research assistants), for 3 sessions a week for 12 months. The primary outcome is the change in the Montreal Cognitive Assessment (MoCA) score from baseline. The secondary outcomes include functional independence, psychological well-being, sleep quality, and health-related quality of life. The outcomes will be assessed at baseline and once bimonthly thereafter, totaling 7 sessions. A linear mixed-effect model will be applied to compare the primary and secondary outcomes. Three blood samples will be collected at baseline, 6 months, and 12 months, respectively, and the baseline blood sample will be immediately measured for the measurement of plasma Aβ42, Aβ40, p-tau181, and p-tau217, blood glial fibrillary acidic protein (GFAP) and neurofilament light chain protein (NfL). Repeated two-way variance (ANOVA) will be used to detect significant differences in blood biomarkers between the two groups. Linear regression will be conducted to examine inter-correlations between clinical outcomes and biomarker levels. Health and social care resource use will additionally be recorded at baseline, 6 months, and 12 months for the economic evaluation to examine the cost-effectiveness of the CAE intervention compared with LAC.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

have at least one of the following abnormal plasma amyloid and tau levels: Aβ42/Aβ40 ratio ≤ 0.17, p-tau217 > 0.15 pg/ml, or/and p-tau181 > 3.3 pg/ml

have mild neurocognitive disorder with the Montreal Cognitive Assessment, Hong Kong version (HK-MoCA) in classifying mild neurocognitive disorder, in which mild neurocognitive disorder is defined as those whose HK-MoCA score falls between the 16th and 2nd percentile of his/her peers adjusted for age and education

Disqualifiers

show moderate-to-severe dementia, as evidenced by a HK-MoCA score falling below the 2nd percentile of his/her peers adjusted for age and education

cannot proficiently communicate due to language function impairment

have severe skin lesions on acupressure areas

had a surgery on the head or neck

Trial design

Design model

Parallel

Treatments tested in this trial

  • Comfy Acupressure for the Elderly

    Procedure/Surgery

    CAE consists of 12 steps, which need about 15 minutes to complete and concentrate on the acupoints on the face, head, neck, shoulder, and hand. CAE intervention will be conducted 3 times per week for 12 consecutive months by trained research assistants.

  • Least acupressure control

    Procedure/Surgery

    LAC consists of three acupoints in the head, neck/shoulder, and hand: Tongtian (BL7), Jianzhen (SI9), and Shousanli (LI10). The completion of one LAC session needs about 3 to 4 minutes. LAC intervention will be conducted 3 times per week for 12 consecutive months by trained research assistants.

Treatment groups

188 Participants
are divided into 2 treatment groups
Group A: Comfy Acupressure for the Elderly (CAE)Experimental treatment 1 intervention
Group B: Least acupressure control (LAC)Sham comparator 1 intervention

Trial outcomes

Primary outcomes

1

Change in the Montreal Cognitive Assessment

The Montreal Cognitive Assessment (MoCA) is used to measure cognitive function , which contains visuospatial, language, concentration, working memory, memory recall, and orientation domains. Its overall score ranges from 0 to 30. A higher score indicates a better cognitive function.

Time frame
Baseline, Month 2, Month 4, Month 6, Month 8, Month 10, Month 12

Secondary outcomes

1

Change in the Digit Span Forward

The Digit Span Forward (DSF) is used to measure short-term auditory-verbal memory and attention and its overall score ranges from 0 to 14. A higher score indicates a better function.

Time frame
Baseline, Month 2, Month 4, Month 6, Month 8, Month 10, Month 12
2

Change in the Digit Span Reverse

The Digit Span Reverse (DSR) is used to measure Digit Span Forward (DSF) is used to measure working memory, cognitive control, and executive function and its overall score ranges from 0 to 14. A higher score indicates a better function.

Time frame
Baseline, Month 2, Month 4, Month 6, Month 8, Month 10, Month 12
3

Change in the Quality of Life in Alzheimer's Disease

The Quality of Life in Alzheimer's Disease (QOL-AD) is used to measure quality of life, rated by both self and caregivers to measure physical health, energy, mood, living situation, memory, family, marriage, friends, self as a whole, ability to do chores, ability to do things for fun, money and life as a whole. Its overall score ranges from 13 to 52. A higher score indicates a better quality of life.

Time frame
Baseline, Month 2, Month 4, Month 6, Month 8, Month 10, Month 12
4

Change in the 5-level EQ-5D version

The 5-level EQ-5D version (EQ-5D-5L) is used to measure health-related quality of life. It comprises five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each with five response levels (1 = no problems, 5 = extreme problems/unable to do), together with a visual analogue scale (EQ VAS) on which respondents rate their health today from 0 (the worst health you can imagine) to 100 (the best health you can imagine). A lower score in the five dimensions indicates a better quality of life, while a higher score in the EQ VAS indicates a better health.

Time frame
Baseline, Month 2, Month 4, Month 6, Month 8, Month 10, Month 12

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: